Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In an ancillary study of Multi-Ethnic Study of Atherosclerosis conducted at one site, we evaluated the performance of the CKD-EPI equations for creatinine (eGFRcr), cystatin C (eGFRcys) or the combination (eGFRcr-cys) compared with GFR measured as plasma clearance of iohexol.
|
28505377 |
2018 |
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, cystatin C is a potentially useful marker of early-stage atherosclerosis.
|
29453992 |
2018 |
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
An imbalance in expression between cathepsins (such as cathepsins S, K, L, C) and their inhibitor cystatin C may favor proteolysis of ECM in the pathogenesis of cardiovascular disease such as atherosclerosis, aneurysm formation, restenosis, and neovascularization.
|
28978867 |
2018 |
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Serum cystatin C level was significantly associated with subclinical atherosclerosis.
|
29090609 |
2018 |
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
GFR was assessed using new improved equation using serum creatinine and cystatin C. Sonar guided renal specimen was obtained and evaluated for the severity of global sclerosis (GS), segmental sclerosis (SS), tubular atrophy (TA), interstitial fibrosis (IF), arterial sclerosis (AS) and arteriolar hyalinosis (AH).
|
29193529 |
2018 |
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
EAT accumulation and elevated cystatin C have been independently regarded as risk factors influencing atherosclerosis.
|
28922364 |
2017 |
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated the association of serum CysC with renal function, CV risk factors, inflammation, and subclinical atherosclerosis in Systemic Lupus Erythematosus (SLE) patients.
|
28914371 |
2017 |
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the Atherosclerosis Risk in Communities Study (n = 13,277 from 4 US communities), we used structural equation modeling to estimate the association between serum 1,5-AG levels and end-stage renal disease (ESRD) from baseline (1990-1992) through 2013 with adjustment for demographics, risk factors, a latent variable for glycemia (diabetes status, fasting glucose, glycated hemoglobin (HbA1c), fructosamine, glycated albumin), and a latent variable for kidney function (creatinine, cystatin C, β2-microglobulin).
|
28535187 |
2017 |
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The association between cystatin C and renal function is well known, however, cystatin C has recently emerged as a strong predictor of cardiovascular events and adverse outcomes in patients with and without kidney disease, mostly related to both inflammation and atherosclerosis.
|
27582023 |
2017 |
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we review the clinical and experimental evidence relevant to the role of cathepsins K, L and S and their most abundant endogenous inhibitor, cystatin C, in atherosclerosis and in obesity.
|
20417681 |
2010 |
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We hypothesize that decreased systemic CysC levels predispose to accelerated atherosclerosis and development of amyloidosis in patients with RA.
|
17552057 |
2007 |
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cysteine proteases and their inhibitors such as cystatin C are assumed to play an important role in the pathogenesis of atherosclerosis and coronary heart disease (CHD).
|
15860739 |
2005 |
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The potential significance of imbalance in expression between cathepsins and their inhibitor cystatin C in cardiovascular disease has been highlighted by the demonstration of cystatin C deficiency in human atherosclerosis and abdominal aortic aneurysms.
|
14726415 |
2004 |